Alx Oncology Holdings Inc Financials

ALXO

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Alx Oncology Holdings Inc (ALXO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Alx Oncology Holdings Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.90x

For every $1 of reported earnings, Alx Oncology Holdings Inc generates $0.90 in operating cash flow (-$121.9M OCF vs -$134.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-82.4x

Alx Oncology Holdings Inc earns $-82.4 in operating income for every $1 of interest expense (-$142.5M vs $1.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$141.6M

YoY+16.4%

Alx Oncology Holdings Inc's EBITDA was -$141.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.4% from the prior year.

Free Cash Flow

-$122.4M

YoY+7.0%

Alx Oncology Holdings Inc generated -$122.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 7.0% from the prior year.

Net Income

-$134.8M

YoY+16.1%

Alx Oncology Holdings Inc reported -$134.8M in net income in fiscal year 2024. This represents an increase of 16.1% from the prior year.

EPS (Diluted)

$-2.58

YoY+31.0%

Alx Oncology Holdings Inc earned $-2.58 per diluted share (EPS) in fiscal year 2024. This represents an increase of 31.0% from the prior year.

Cash & Debt

$17.6M

YoY-21.6%

5Y CAGR+14.3%

Alx Oncology Holdings Inc held $17.6M in cash against $9.5M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

53M

YoY+6.2%

5Y CAGR+75.7%

Alx Oncology Holdings Inc had 53M shares outstanding in fiscal year 2024. This represents an increase of 6.2% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$116.4M

YoY-17.9%

5Y CAGR+48.1%

Alx Oncology Holdings Inc invested $116.4M in research and development in fiscal year 2024. This represents a decrease of 17.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$447K

YoY-64.9%

5Y CAGR+4.8%

Alx Oncology Holdings Inc invested $447K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 64.9% from the prior year.

ALXO Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	$0	$0-100.0%	$1.2M-75.4%	$4.8M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$116.4M-17.9%	$141.8M+44.1%	$98.4M+63.5%	$60.2M+107.8%	$29.0M+77.6%	$16.3M
SG&A Expenses	$26.1M-8.4%	$28.5M-1.9%	$29.0M+24.2%	$23.4M+57.9%	$14.8M+347.0%	$3.3M
Operating Income	-$142.5M+16.3%	-$170.3M-33.6%	-$127.4M-52.5%	-$83.6M-91.4%	-$43.7M-127.6%	-$19.2M
Interest Expense	$1.7M+10.5%	$1.6M+557.6%	$238K+1730.8%	$13K	N/A	N/A
Income Tax	N/A	N/A	$64K+404.8%	-$21K-108.7%	$241K+608.8%	$34K
Net Income	-$134.8M+16.1%	-$160.8M-30.2%	-$123.5M-47.9%	-$83.5M-82.5%	-$45.7M-137.7%	-$19.2M
EPS (Diluted)	$-2.58+31.0%	$-3.74-23.4%	$-3.03-46.4%	$-2.07+25.0%	$-2.76	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$17.4M-34.1%	$26.5M	N/A	$45.8M	N/A	$29.4M	N/A	$18.2M
SG&A Expenses	$5.1M-16.5%	$6.1M	N/A	$7.5M	N/A	$7.3M	N/A	$6.4M
Operating Income	-$22.5M+30.8%	-$32.6M	N/A	-$53.3M	N/A	-$36.7M	N/A	-$24.6M
Interest Expense	$408K-8.5%	$446K	N/A	$391K	N/A	$2K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$22.1M+27.9%	-$30.7M	N/A	-$51.0M	N/A	-$35.3M	N/A	-$24.6M
EPS (Diluted)	$-0.41+29.3%	$-0.58	N/A	$-1.24	N/A	$-0.87	N/A	$-0.61

ALXO Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$147.8M-39.1%	$242.6M-20.9%	$306.5M-19.4%	$380.2M-12.8%	$436.1M+3984.4%	$10.7M
Current Assets	$134.4M-28.8%	$188.7M-30.4%	$271.0M-26.2%	$367.0M-15.8%	$436.0M+4344.8%	$9.8M
Cash & Equivalents	$17.6M-21.6%	$22.4M-54.1%	$48.8M-86.6%	$363.7M-16.2%	$434.2M+4715.6%	$9.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$34.2M-35.4%	$52.8M+22.8%	$43.0M+151.1%	$17.1M+176.0%	$6.2M-92.4%	$81.3M
Current Liabilities	$18.5M-48.6%	$36.0M+27.1%	$28.3M+85.2%	$15.3M+146.5%	$6.2M+24.5%	$5.0M
Long-Term Debt	$9.5M-1.8%	$9.6M+2.7%	$9.4M	N/A	N/A	$5.4M
Total Equity	$113.6M-40.1%	$189.7M-28.0%	$263.5M-27.4%	$363.0M-15.5%	$429.8M+708.5%	-$70.6M
Retained Earnings	-$621.1M-27.7%	-$486.3M-49.4%	-$325.5M-61.1%	-$202.0M-70.4%	-$118.5M-62.8%	-$72.8M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Total Assets	$82.7M-44.0%	$147.8M-39.1%	$242.6M+10.2%	$220.1M-28.2%	$306.5M-3.5%	$317.7M-16.4%	$380.2M-4.9%	$399.7M
Current Assets	$66.5M-50.5%	$134.4M-28.8%	$188.7M-5.2%	$199.1M-26.5%	$271.0M-6.8%	$290.8M-20.8%	$367.0M-5.6%	$389.0M
Cash & Equivalents	$23.4M+33.4%	$17.6M-21.6%	$22.4M+14.4%	$19.6M-59.9%	$48.8M-0.5%	$49.1M-86.5%	$363.7M-5.6%	$385.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$37.9M+11.0%	$34.2M-35.4%	$52.8M+2.9%	$51.4M+19.4%	$43.0M+40.0%	$30.7M+79.3%	$17.1M+17.7%	$14.6M
Current Liabilities	$27.7M+49.8%	$18.5M-48.6%	$36.0M+2.4%	$35.1M+24.1%	$28.3M+12.2%	$25.2M+65.0%	$15.3M+22.5%	$12.5M
Long-Term Debt	$5.8M-39.1%	$9.5M-1.8%	$9.6M+0.7%	$9.6M+2.0%	$9.4M	N/A	N/A	N/A
Total Equity	$44.8M-60.6%	$113.6M-40.1%	$189.7M+12.4%	$168.8M-35.9%	$263.5M-8.2%	$287.0M-21.0%	$363.0M-5.7%	$385.2M
Retained Earnings	-$700.0M-12.7%	-$621.1M-27.7%	-$486.3M-10.3%	-$440.8M-35.4%	-$325.5M-10.4%	-$294.8M-45.9%	-$202.0M-16.4%	-$173.5M

ALXO Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$121.9M+6.5%	-$130.4M-46.1%	-$89.2M-31.0%	-$68.1M-77.9%	-$38.3M-168.7%	-$14.2M
Capital Expenditures	$447K-64.9%	$1.3M-10.7%	$1.4M+114.3%	$666K+2048.4%	$31K-91.2%	$353K
Free Cash Flow	-$122.4M+7.0%	-$131.6M-45.2%	-$90.7M-31.8%	-$68.8M-79.5%	-$38.3M-162.4%	-$14.6M
Investing Cash Flow	$86.3M+93.2%	$44.7M+119.0%	-$235.4M-4682.0%	-$4.9M-907.0%	$610K+272.8%	-$353K
Financing Cash Flow	$30.8M-48.0%	$59.3M+501.3%	$9.9M+298.9%	$2.5M-99.5%	$462.9M+2914.1%	$15.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Operating Cash Flow	-$17.1M+46.7%	-$32.0M+19.2%	-$39.7M-27.3%	-$31.2M-50.8%	-$20.7M+33.1%	-$30.9M-76.6%	-$17.5M+29.6%	-$24.9M
Capital Expenditures	$56K-6.7%	$60K-59.5%	$148K+111.4%	-$1.3M-435.0%	$389K+102.6%	$192K-26.4%	$261K-34.4%	$398K
Free Cash Flow	-$17.1M+46.6%	-$32.1M+19.4%	-$39.8M-22.7%	-$32.5M-54.2%	-$21.1M+32.2%	-$31.1M-75.1%	-$17.7M+29.7%	-$25.3M
Investing Cash Flow	$21.4M-35.5%	$33.2M+299.1%	-$16.7M-230.1%	$12.8M+17.1%	$10.9M-20.1%	$13.7M+403.1%	-$4.5M-1035.2%	-$398K
Financing Cash Flow	-$159K-148.5%	$328K-99.4%	$59.2M+53402.7%	-$111K-101.2%	$9.5M+7080.9%	-$136K-126.0%	$524K+19.4%	$439K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ALXO Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-3694.0%-3294.0pp	-400.0%
Net Margin	N/A	N/A	N/A	N/A	-3869.7%-3468.5pp	-401.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-91.3%-24.9pp	-66.3%-26.0pp	-40.3%-18.3pp	-21.9%-11.5pp	-10.5%+169.8pp	-180.3%
Current Ratio	7.26+2.0	5.24-4.3	9.57-14.4	24.00-46.3	70.28+68.3	1.97
Debt-to-Equity	0.08+0.0	0.05+0.0	0.04-0.0	0.05+0.0	0.01+0.1	-0.08
FCF Margin	N/A	N/A	N/A	N/A	-3242.0%-2937.5pp	-304.5%

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-26.8%-10.2pp	-16.5%	N/A	-23.2%	N/A	-11.1%	N/A	-6.2%
Current Ratio	2.40-4.9	7.26+2.0	5.24-0.4	5.66-3.9	9.57-2.0	11.52-12.5	24.00-7.2	31.15
Debt-to-Equity	0.13+0.0	0.08+0.0	0.050.0	0.06+0.0	0.04-0.1	0.11+0.1	0.050.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Mink Therapeutics, Inc. INKT

$51.8M

ARTIVA BIOTHERAPEUTICS INC ARTV

$98.2M

Werewolf Therapeutics, Inc. HOWL

$31.7M

Applied Therapeutics APLT

$14.9M

Cue Biopharma Inc CUE

$28.0M

Frequently Asked Questions

Is Alx Oncology Holdings Inc profitable?

No, Alx Oncology Holdings Inc (ALXO) reported a net income of -$134.8M in fiscal year 2024.

What is Alx Oncology Holdings Inc's earnings per share (EPS)?

Alx Oncology Holdings Inc (ALXO) reported diluted earnings per share of $-2.58 for fiscal year 2024. This represents a 31.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Alx Oncology Holdings Inc's EBITDA?

Alx Oncology Holdings Inc (ALXO) had EBITDA of -$141.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Alx Oncology Holdings Inc have?

As of fiscal year 2024, Alx Oncology Holdings Inc (ALXO) had $17.6M in cash and equivalents against $9.5M in long-term debt.

What is Alx Oncology Holdings Inc's free cash flow?

Alx Oncology Holdings Inc (ALXO) generated -$122.4M in free cash flow during fiscal year 2024. This represents a 7.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Alx Oncology Holdings Inc's operating cash flow?

Alx Oncology Holdings Inc (ALXO) generated -$121.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Alx Oncology Holdings Inc's total assets?

Alx Oncology Holdings Inc (ALXO) had $147.8M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Alx Oncology Holdings Inc's capital expenditures?

Alx Oncology Holdings Inc (ALXO) invested $447K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Alx Oncology Holdings Inc spend on research and development?

Alx Oncology Holdings Inc (ALXO) invested $116.4M in research and development during fiscal year 2024.

How many shares does Alx Oncology Holdings Inc have outstanding?

Alx Oncology Holdings Inc (ALXO) had 53M shares outstanding as of fiscal year 2024.

What is Alx Oncology Holdings Inc's current ratio?

Alx Oncology Holdings Inc (ALXO) had a current ratio of 7.26 as of fiscal year 2024, which is generally considered healthy.

What is Alx Oncology Holdings Inc's debt-to-equity ratio?

Alx Oncology Holdings Inc (ALXO) had a debt-to-equity ratio of 0.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Alx Oncology Holdings Inc's return on assets (ROA)?

Alx Oncology Holdings Inc (ALXO) had a return on assets of -91.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Alx Oncology Holdings Inc's cash runway?

Based on fiscal year 2024 data, Alx Oncology Holdings Inc (ALXO) had $17.6M in cash against an annual operating cash burn of $121.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Alx Oncology Holdings Inc's Piotroski F-Score?

Alx Oncology Holdings Inc (ALXO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Alx Oncology Holdings Inc's earnings high quality?

Alx Oncology Holdings Inc (ALXO) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Alx Oncology Holdings Inc cover its interest payments?

Alx Oncology Holdings Inc (ALXO) has an interest coverage ratio of -82.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.